Belle Mead, NJ, United States of America

Chang-Sun Lee

USPTO Granted Patents = 11 (Patent Applications = 1)

CIPO Patents = 2

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 7.8

ph-index = 2

Forward Citations = 67(Granted Patents)

Company Filing History:

8 out of 183

Ptc Therapeutics, Inc.

patents

3 out of 168

F. Hoffmann-la Roche Ag

where one patent can have more than one assignee

Years Active: 2012-2021

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11180483 - Substituted reverse pyrimidine Bmi-1 inhibitors (2021-11-23),

2. 10584115 - Substituted pyridine and pyrazine BMI-1 inhibitors (2020-03-10),

3. RE47689 - Compounds for treating spinal muscular atrophy (2019-11-04),

4. 10428050 - Substituted reverse pyrimidine Bmi-1 inhibitors (2019-10-01),

5. 10370371 - Substituted pyrimidine Bmi-1 inhibitors (2019-08-06),

6. 9975878 - Substituted triazine BMI-1 inhibitors (2018-05-22),

7. 9617268 - Compounds for treating spinal muscular atrophy (2017-04-11),

8. 9371336 - Compounds for treating spinal muscular atrophy (2016-06-21),

9. 9371281 - Indole derivatives as inhibitors of histone deacetylase (2016-06-21),

10. 8900565 - Indole derivatives as inhibitors of histone deacetylase (2014-12-02),

11. 8338416 - Indole derivatives as inhibitors of histone deacetylase (2012-12-25),

Title: Chang-Sun Lee: Innovator in Cancer Treatment

Introduction

Chang-Sun Lee is a prominent inventor based in Belle Mead, NJ (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of various compounds. With a total of 11 patents to his name, Lee's work focuses on inhibiting specific proteins associated with cancer progression.

Latest Patents

Among his latest patents are the "Substituted reverse pyrimidine Bmi-1 inhibitors" and "Substituted pyridine and pyrazine BMI-1 inhibitors." These patents describe amine substituted compounds that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein. The methods outlined in these patents aim to treat cancers mediated by Bmi-1, showcasing Lee's commitment to advancing cancer therapies.

Career Highlights

Throughout his career, Chang-Sun Lee has worked with notable companies such as PTC Therapeutics, Inc. and F. Hoffmann-La Roche AG. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Lee has collaborated with talented individuals, including Wu Du and Ramil Y Baiazitov. These partnerships have further enhanced his research capabilities and have led to significant advancements in cancer treatment.

Conclusion

Chang-Sun Lee's innovative work in developing Bmi-1 inhibitors represents a crucial step forward in cancer therapy. His dedication to research and collaboration continues to impact the medical field positively.

This text is generated by artificial intelligence and may not be accurate.